Sobi Market Share Analysis for November 2025

Disclosure of Payments to Healthcare Collaboration between healthcare providers and the Pharmaceutical industry has for long been a positive driver for advancements in patient care and progression of innovative medicine.  Healthcare professionals (HCPs) and healthcare organisations (HCOs) are valuable partners for Sobi. As experts in their field, they provide us with first-hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet various patient needs. As part of our mission to improve life for people with rare diseases, by developing and delivering innovative therapies, we seek to bring greater transparency to an already well-regulated industry. In order to secure future collaboration, strengthen our relationships with HCPs and HCOs and to increase public awareness, Sobi is committed to meeting applicable spend transparency requirements.  Sobi currently publishes transfer of value (in cash and kind) made to healthcare providers in 33 markets across Europe (including Russia and Ukraine) as well as the US. Disclosure in each market is described in more detail below.  If you have any questions about the payments disclosed by Sobi please use the e-mail address info@sobi.com. In order for us to be able to quickly respond please state “Transparency” in the subject field. Payments made to European healthcare Sobi supports the European Federation of Pharmaceutical Industries and Association’s (EFPIA) Code of Practice in Europe. Since 2016 we have disclosed the transfers of value we make to HCPs and HCOs on an individual named basis as far as possible. This includes for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. Disclosure information is